Evidence map›Paper›PMID 23713087›Full record

ArticleNeurology2013

Why our patients (and we) need basic science research.

Nina F Schor

Abstract read
In one paragraph

Article in Neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Basic science is not just a foundation.Nature cell biology · 2024
    Article
  4. Review
  5. Effect ofPlants (Basel, Switzerland) · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Nina F SchorDepartment of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. nina_schor@urmc.rochester.edu

Funding

NEUROTROPHIC MECHANISMS IN NEUROBLASTOMAR01NS038569 · NINDS · UNIVERSITY OF ROCHESTER · PI SCHOR, NINA F · 2000 to 2008
$2.4M
TARGETED THERAPY FOR CHEMORESISTANT TUMORSR01CA074289 · NCI · UNIVERSITY OF ROCHESTER · PI SCHOR, NINA F · 1998 to 2006
$1.6M
Antioxidant Strategies for Parkinson's DiseaseR01NS041297 · NINDS · UNIVERSITY OF ROCHESTER · PI SCHOR, NINA F · 2002 to 2005
$1.2M
NCI NIH HHS R01-CA074289NINDS NIH HHS R01-NS038569NINDS NIH HHS R01-NS041297
6 · The paper itself

Abstract

In times of fiscal austerity, the tendency is to seek instant, inexpensive gratification. In the case of biomedical research, this means the shortest path to practical clinical implementation. But fueling the translational pipeline with discovery depends critically on allowing the biomedical research community to follow their science where it takes them. Fiscal constraints carry with them the risk of squelching creativity and forfeiting the power of serendipity to provide the substrate for the translational engine in the future.

Indexed as

Biomedical ResearchNervous System DiseasesNeurologyTranslational Research, BiomedicalAnimalsHumansWorkforce

Identifiers

PMID23713087
PMCPMC3716401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.